Evidence map›Paper›PMID 39907870›Full record

ArticleHead and neck pathology2025

STAT3 Expression in Organ-Preserved Laryngeal Carcinomas: Correlation with Treatment Resistance and Conventional Parameters.

Esra Nur Bayır, Ünsal Han, Ömer Bayır, Seda Işık, Güleser Saylam, Doğan Yazılıtaş, Mustafa Cengiz, Mehmet Hakan Korkmaz

Abstract read
In one paragraph

Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Esra Nur BayırAnkara Etlik City Hospital, Department of Pathology, Ankara, Türkiye. esranrbyr@gmail.com.
Ünsal HanAnkara Etlik City Hospital, Department of Pathology, Ankara, Türkiye.
Ömer BayırAnkara Etlik City Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Ankara, Türkiye.
Seda IşıkÇankırı State Hospital, Otolaryngology Clinic, Çankırı, Türkiye.
Güleser SaylamLokman Hekim Unıversıty, Faculty of Medicine, Department of Otolaryngology And Head And Neck Surgery, Ankara, Türkiye.
Doğan YazılıtaşDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara, Türkiye.
Mustafa CengizFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Türkiye.
Mehmet Hakan KorkmazPrivate Clinic, Otolaryngology and Head and Neck Surgery, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the major challenges in the treatment of laryngeal squamous cell carcinoma (LSCC) with organ-preserving therapies is the emergence of treatment resistance. The JAK/STAT pathway has been increasingly implicated in this resistance, particularly through the overexpression or persistent activation of STAT3. Increased STAT3 expression is thought to be associated with resistance to radiotherapy and/or chemotherapy, and STAT3 inhibitors have been proposed as potential targeted treatments.

objectivesThe primary objective of this study is to investigate the relationship between STAT3 expression and treatment resistance in patients with LSCC undergoing organ-preserving therapy and to evaluate the association between STAT3 expression and clinical/histopathologic prognostic parameters. A secondary objective is to evaluate STAT3 expression in diagnostic biopsies and laryngectomy specimens from treatment-resistant patients to investigate the potential predictability of treatment resistance from initial biopsy specimens. METHODOLOGY: The study included 123 patients diagnosed with LSCC between 2008 and 2022, all of whom received nonsurgical treatment. Patients were divided into two groups based on their response to treatment: treatment-sensitive patient group (TSPG) and treatment-resistant patient group (TRPG). Immunohistochemical staining for p-STAT3 was performed on a diagnostic biopsy for each TSPG patient and on both pre- and post-treatment biopsies for each TRPG patient. STAT3 expression levels were scored and their association with treatment resistance, clinical and pathological parameters was analysed.

resultsNo statistically significant difference in p-STAT3 expression was found between the two groups. TSPG patients were significantly older at diagnosis (p = 0.038), and tumor location differed between groups (p = 0.001). No significant differences in histopathologic or clinical prognostic parameters were observed between patients with high and low STAT3 expression. In addition, no significant difference in STAT3 staining was found between diagnostic biopsies and laryngectomy specimens in TRPG patients.

conclusionSTAT3 expression was not associated with treatment resistance in LSCC, and its expression level did not correlate with prognostic parameters or survival outcomes. Therefore, STAT3 does not appear to be a useful biomarker for predicting treatment resistance or prognosis in LSCC.

Indexed as

Biomarkers, TumorLaryngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSTAT3 Transcription FactorAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedOrgan Sparing TreatmentsBiomarkers, TumorSTAT3 protein, humanSTAT3 Transcription FactorLaryngeal squamous cell carcinomaSTAT3Treatment resistance

Identifiers

PMID39907870
PMCPMC11799471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.